Изолированная регионарная перфузия в комбинированном лечении пациентов с саркомами мягких тканей конечностей
Аннотация
Саркомы мягких тканей (СМТ) – гетерогенная группа опухолей, в которую включено около 50 подтипов. в большинстве случаев СМТ локализуются на конечностях. целью исследования является анализ возможностей применения метода изолированной регионарной перфузии конечностей в лечении сарком мягких тканей. по данным крупных исследований, доля ответов после ИРП составляет 70%, в то время как полный ответ развивается в 20% случаев. Несмотря на многочисленные исследования, их довольно оптимистические результаты, проблема лечения местнораспространенных сарком мягких тканей конечностей до конца не решена. Для увеличения эффективности ИРП с мелфаланом и более широкого ее применения в практике специализированных клиник необходимо четко отработать основные параметры ее проведения, четко сформировать критерии отбора пациентов к комплексному и комбинированному лечению с применением ИРП.
Об авторе
Н. С. Петроченко
ФГБНУ «Российский онкологический научный центр им. Н.Н. Блохина»
Россия
Россия
г. Москва
Список литературы
1. Bonvalot S., Rimareix F., Causeret S. et al. Hyperthermic isolated limb perfusion in locally advanced soft tissue sarcoma and progressive desmoid-type fibromatosis with TNF 1 mg and melphalan (T1-M HILP) is safe and efficient. Ann. Surg. Oncol. 2009, v. 16 (2), p. 3350-3357.
2. Casali P.G. Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. Ann. Oncol. 2012, v. 23 (Suppl. 10): p. 167-169.
3. Cherix S., Speiser M., Matter M. et al. Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J. Surg. Oncol. 2008, v. 98 (3), p. 148-155.
4. Cormier J.N., Langstein H.N., Pisters P.W. Preoperative therapy for soft tissue sarcoma. Cancer Treat. Res. 2004, v. 120, p. 43-63.
5. Cormier J.N., Pollock R.E. Soft tissue sarcomas. CA Cancer J. Clin. 2004, v. 54 (2), p. 94-109.
6. Deroose J.P., van Geel A.N., Burger J.W., Eggermont A.M., Verhoef C. Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients. J. Surg. Oncol. 2012, v. 105, p. 563-569.
7. Deroose J.P., Burger J.W., van Geel A.N., den Bakker M.A., de Jong J.S., EggermontA.M., Verhoef C. Radiotherapy for soft tissue sarcomas after isolated limb perfusion and surgical resection: essential for local control in all patients? Ann. Surg. Oncol. 2011, v. 18, p. 321-327.
8. Deroose J.P., Eggermont A.M., van Geel A.N., Burger J.W., den Bakker M.A., de Wilt J.H., Verhoef C. Long-term results of tumor necrosis factor α- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. J. Clin. Oncol. 2011, v. 29, p. 4036-4044.
9. Eggermont A.M., de Wilt J.H., Ten Hagen T.L. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003, v. 4, p. 429-437.
10. Eggermont A.M., Schraffordt Koops H., Klausner J.M. et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann. Surg. 1996, v. 224 (6), p. 756-764.
11. Eggermont A.M., Schraffordt Koops H., Klausner J.M. et al. Isolated limb perfusion with high-dose tumor necrosis factoralpha for locally advanced extremity soft tissue sarcomas. Cancer Treat. Res. 1997, v. 91, p. 189-203.
12. Eilber F.C., Rosen G., Eckardt J., Forscher C., Nelson S.D., Selch M. et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J. Clin. Oncol. 2001, v. 19, p. 3203-3209.
13. Eilber F.C., Dry S.M. Diagnosis and management of synovial sarcoma. J. Surg. Oncol. 2008, v. 97, p. 314-320.
14. Ferguson P.C. Surgical considerations for management of distal extremity soft tissue sarcomas. Curr. Opin. Oncol. 2005, v. 17, p. 366-369.
15. Ferrari A., GronchiA., Casanova M., Meazza C., Gandola L., Collini P. et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004, v. 101, p. 627-634.
16. Grabellus F., Stylianou E., Umutlu L., Sheu S.Y., Lehmann N., Taeger G., Lauenstein T. Size-based clinical response evaluation is insufficient to assess clinical response of sarcomas treated with isolated limb perfusion with TNFα and melphalan. Ann. Surg. Oncol. 2012, v. 19, p. 3375-3385.
17. Grabellus F., Kraft C., Sheu S.Y., Ebeling P., Bauer S., Lendemans S. et al. Evaluation of 47 soft tissue sarcoma resection specimens after isolated limb perfusion with TNFα and melphalan: histologically characterized improved margins correlate with absence of recurrences. Ann. Surg. Oncol. 2009, v. 16 (3), p. 676-686.
18. Grunhagen D.J., De Wilt J.H., Ten Hagen T.L., EggermontA.M. Technology insight: utility of TNFα-based isolated limb perfusion to avoid amputation of unresectable tumors of the extremities. Nat. Clin. Pract. Oncol. 2006, v. 3, p. 94-103.
19. Grunhagen D.J., De Wilt J.H., Graveland W.J. et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limbthreatening soft tissue sarcoma. Cancer. 2006, v. 106 (8), p. 1776-1784.
20. Guillou L., Benhattar J., BonichonF., Gallagher G., TerrierP., Stauffer E. et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J. Clin. Oncol. 2004, v. 22, p. 4040-4050.
21. Gutman M., Inbar M., Lev-Shlush D. et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a 90% response rate and limb preservation. Cancer. 1997, v. 79 (6), p. 1129-1137.
22. Hoven-Gondrie M.L., Thijssens K.M., Geertzen J.H. et al. Isolated limb perfusion and external beam radiotherapy for soft tissue sarcomas of the extremity: long-term effects on normal tissue according to the LENT-SOMA scoring system. Ann. Surg. Oncol. 2008, v. 15 (5), p. 1502-1510.
23. Hoven-Gondrie M.L., Thijssens K.M., Van den Dungen J.J, et al. Long-term locoregional vascular morbidity after isolated limb perfusion and external-beam radiotherapy for soft tissue sarcoma of the extremity. Ann. Surg. Oncol. 2007, v. 14 (7), p. 2105-2112.
24. Jaffe C.C. Measures of response: RECIST, WHO, and new alternatives. J. Clin. Oncol. 2006, v. 24, p. 3245-3251.
25. Kalman P.G., Lipton I.H., Provan J.L. et al. Radiation damage to large arteries. Can. J. Surg. 1983, v. 26 (1), p. 88-91.
26. Khanfir K., Alzieu L., Terrier P. et al. Does adjuvant radiation therapy increase loco-regional control after optimal resection of soft-tissue sarcoma of the extremities? Eur. J. Cancer. 2003, v. 39 (13), p. 1872-1880.
27. Ladanyi M., Antonescu C.R., Leung D.H., Woodruff J.M., KawaiA., Healey J.H. et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002, v. 62, p. 135-140.
28. Milbeo Y., Kantor G., Laharie H. et al. Adjuvant radiation therapy for soft tissue sarcoma of the extremities: analysis of local control according to volume and dose. Cancer Radiother. 2005, v. 9 (5), p. 293-303.
29. Noorda E.M., Vrouenraets B.C., Nieweg O.E. et al. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer. 2003, v. 98 (7), p. 1483-1490.
30. Pennacchioli E., Deraco M., Mariani L. et al. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. Ann. Surg. Oncol. 2007, v. 14 (2), p. 553-559.
31. Pisters P.W., Pollock R.E., Lewis V.O. et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann. Surg. 2007, v. 246 (4), p. 675-681.
32. Pisters P.W., Leung D.H., Woodruff J. et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J. Clin. Oncol. 1996, v. 14 (5), p. 1679-1689.
33. Rosenberg S.A., Tepper J., Glatstein E. et al. The treatment of softtissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann. Surg. 1982, v. 196 (3), p. 305-315.
34. Schwindenhammer В., Podleska L.E., Kutritz1 A., Bauer S., Sien-Yi Sheu1, Taeger G. et al. The pathologic response of resected synovial sarcomas to hyperthermic isolated limb perfusion with melphalan and TNFα: a comparison with the whole group of resected soft tissue sarcomas. World J. Surg. Oncol. 2013, v. 11, p. 185.
35. Shi W., Indelicato D.J., Morris C.G., Scarborough M.T., Gibbs C.P., Zlotecki R.A. Long-term treatment outcomes for patients with synovial sarcoma: a 40-year experience at the University of Florida. Am. J. Clin. Oncol. 2013, v. 36, p. 83-88.
36. Stojadinovic A., Leung D.H., Allen P. et al. Primary adult soft tissue sarcoma: time-dependent influence of prognostic variables. J. Clin. Oncol. 2002, v. 20 (21), p. 4344-4352.
37. The ESMO / European Sarcoma Network Working Group: Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2012, v. 23 (Suppl. 7), p. 92-99.
38. Thijssens K.M., van Ginkel R.J., Pras E. et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy. Ann. Surg. Oncol. 2006, v. 13 (4), p. 518-524.
39. Van Ginkel R.J., Thijssens K.M., Pras E. et al. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann. Surg. Oncol. 2007, v. 14 (4), p. 1499-1506.
40. Vrouenraets B.C., Keus R.B., Nieweg O.E., Kroon B.B. Complications of combined radiotherapy and isolated limb perfusion with tumor necrosis factor alpha +/- interferon gamma and melphalan in patients with unresectable soft tissue tumors. J. Surg. Oncol. 1997, v. 65 (2), p. 88-94.
41. Vrouenraets B.C., Veld G.J., Nieweg O.E. et al. Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur. J. Surg. Oncol. 1999, v. 25 (5), p. 503-508.
42. Weitz J., Antonescu C.R., Brennan M.F. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J. Clin. Oncol. 2003, v. 21, p. 2719-2725.
43. Williard W.C., Hajdu S.I., Casper E.S., Brennan M.F. Comparison amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann. Surg. 1992, v. 215 (3), p. 269-275.
44. Yang J.C., Chang A.E., Baker A.R. et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J. Clin. Oncol. 1998, v. 16 (1), p. 197-203.
45. Zeytoonjian T., Mankin H.J., Gebhardt M.C., Hornicek F.J. Distal lower extremity sarcomas: frequency of occurrence and patient survival rate. Foot Ankle Int. 2004, v. 25, p. 325-330.
Рецензия
Для цитирования:
Петроченко Н.С. Изолированная регионарная перфузия в комбинированном лечении пациентов с саркомами мягких тканей конечностей. Саркомы костей, мягких тканей и опухоли кожи. 2015;(1):26-31.
For citation:
Petrochenko N.S. Isoleted limb regional perfusion in the combined treatment of patients with soft tissue sarcomas of the limbs. Bone and soft tissue sarcomas, tumors of the skin. 2015;(1):26-31. (In Russ.)
Просмотров:
164
Послать статью по эл. почте 
